Loading clinical trials...
Loading clinical trials...
A Phase III, Double-masked, Randomised, Placebo-controlled Trial Investigating the Safety and Efficacy of Nicotinamide (NAM) to Slow Visual Field Loss in Adults With Open-angle Glaucoma
Conditions
Interventions
Nicotinomide
Matching placebo
Locations
10
United Kingdom
Belfast City Hospital
Belfast, Northern Ireland, United Kingdom
Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, United Kingdom
Queen Victoria Hospital NHS Foundation Trust
East Grinstead, United Kingdom
Royal Liverpool Hospital
Liverpool, United Kingdom
Moorfields Eye Hospital NHS Foundation Trust
London, United Kingdom
Barnet Hospital, Royal Free London NHS Foundation Trust
London, United Kingdom
Start Date
January 18, 2024
Primary Completion Date
April 30, 2027
Completion Date
June 30, 2027
Last Updated
May 9, 2024
NCT06289491
NCT05885022
NCT03870230
NCT06201455
NCT05624398
NCT05325996
Lead Sponsor
University College, London
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions